🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
6.34
-0.43 (-6.35%)
At close: Nov 19, 2026, 4:00 PM EST
6.26
-0.08 (-1.34%)
After-hours: Nov 19, 2026, 7:30 PM EST

Company Description

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.

Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.

It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases.

The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.

Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Atara Biotherapeutics, Inc.
Atara Biotherapeutics logo
CountryUnited States
Founded2012
IPO DateOct 16, 2014
IndustryBiotechnology
SectorHealthcare
Employees10
CEOAnhco Nguyen

Contact Details

Address:
1280 Rancho Conejo Blvd
Thousand Oaks, California 91320
United States
Phone805 623 4211
Websiteatarabio.com

Stock Details

Ticker SymbolATRA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001604464
CUSIP Number046513206
ISIN NumberUS0465132068
Employer ID46-0920988
SIC Code2836

Key Executives

NamePosition
Dr. Anhco Nguyen Ph.D.President, Chief Executive Officer and Director
Kevin G. Sarney CPAInterim Chief Financial Officer
Jim SesicSenior Vice President of Regulatory Affairs

Latest SEC Filings

DateTypeTitle
Nov 17, 2026144Filing
Nov 16, 2026144Filing
Nov 10, 2026S-3Registration statement under Securities Act of 1933
Nov 10, 202610-QQuarterly Report
Nov 10, 20268-KCurrent Report
Aug 26, 2026144Filing
Aug 14, 2026SCHEDULE 13G/AFiling
Aug 12, 202610-QQuarterly Report
Aug 12, 20268-KCurrent Report
Jul 24, 2026SCHEDULE 13D/AFiling
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides